The function of p53 is best understood in response to genotoxic stress, but increasing evidence
suggests that p53 also plays a key role in the regulation of metabolic homeostasis. p53 …

Resistance to therapeutic agents, either intrinsic or acquired, is currently a major problem in
the treatment of cancers and occurs in virtually every type of anti-cancer therapy. Therefore, …

Invariant natural killer T (iNKT) cells are a subpopulation of T cells that are reactive with
glycolipids that are bound by CD1d antigen-presenting molecules. α-Galactosylceramide (α-…

Cancer cells acquire distinct metabolic adaptations to survive stress associated with tumour
growth and to satisfy the anabolic demands of proliferation. The tumour suppressor protein …

The dipeptide boronic acid bortezomib, also termed VELCADE ® , is a proteasome inhibitor
now in use for the treatment of multiple myeloma, and its use for the treatment of other …

The proteasome inhibitor bortezomib is a novel anticancer drug that has shown promise in
the treatment of refractory multiple myeloma. However, its clinical efficacy has been …

Stable Foxp3 expression is required for the development of functional regulatory T (Treg)
cells. Here, we demonstrate that the expression of the transcription factor Foxp3 can be …

Proteasome inhibitors, such as the dipeptide boronic acid bortezomib, are emerging as
important tools in the treatment of the fatal hematologic malignancy multiple myeloma. Despite …

We describe a two-dimensional thermal proteome profiling strategy that can be combined with
an orthogonal chemoproteomics approach to enable comprehensive target profiling of the …

The proteasome is an essential evolutionary conserved protease involved in many
regulatory systems. Here, we describe the synthesis and characterization of the activity-based, …